The Efficacy of Drug-eluting Bead Transarterial Chemoembolization Loaded With Oxaliplatin for the Treatment of Stage III-IV Non-small-cell Lung Cancer

Wang, Jianan; Li, Yahua; Li, Zong-Ming; Zhou, Zihe; Li, Yifan; Han, Xinwei

doi:10.1016/j.acra.2022.01.015

Cited by 6 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67,70 Drug-eluting beads TACE (DEB-TACE), a recent novel technique, aims to solve this problem by taking advantage of the slow and sustained release of the chemotherapy from the beads into the local tumor environment. 67,[71][72][73] Moreover, different kinds of drugs can be used for DEB-TACE, such as doxorubicin, 74 gemcitabine, 67,75 oxaliplatin, 76,77 and pirarubicin. 78 These methods work because the lung has a dual blood supply, as previously described.…”

Section: Transarterial Therapies For Lung Cancersmentioning

confidence: 99%

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Mansur

Garg

Camacho

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer mortality in the world. A significant proportion of patients with lung cancer are not candidates for surgery and must resort to other treatment alternatives. Rapid technological advancements in fields like interventional radiology have paved the way for valid treatment modalities like image-guided percutaneous and transarterial therapies for treatment of both primary and metastatic lung cancer. The rationale of ablative therapies relies on the fact that focused delivery of energy induces tumor destruction and pathological necrosis. Image-guided percutaneous thermal ablation therapies are established techniques in the local treatment of hepatic, renal, bone, thyroid, or uterine lesions. In the lung, the 3 main indications for lung ablation include local curative intent, a strategy to achieve a chemoholiday in oligometastatic disease, and recently, oligoprogressive disease. Transarterial therapies include a set of catheter-based treatments that involve delivering embolic and/or chemotherapeutic agents directed into the target tumor via the supplying arteries. This article provides a comprehensive review of the various techniques available and discusses their applications and associated complications in primary and metastatic lung cancer.

show abstract

Section: Transarterial Therapies For Lung Cancersmentioning

confidence: 99%

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Mansur

Garg

Camacho

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…However, traditional embolization materials, including iodized oil, gelatin sponge particles, and polyvinyl alcohol particles, have two major defects, such as incomplete embolization and a high complication rate. As a new embolization material, drug-loaded microspheres have the dual functions of vascular embolization and local sustained release of chemotherapy drugs, and have achieved good clinical effects in treating lung cancer using BACE (7,8). This study prospectively observed the efficacy and safety of CalliSpheres drug-eluting beads (DEB) combined with BACE (DEB-BACE) in treating refractory non-small-cell lung cancer (NSCLC).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Zhao

Liu²,

Qin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to prospectively observe the efficacy and safety of CalliSpheres drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) for refractory non-small-cell lung cancer (NSCLC).MethodsThe interventional therapy plan was as follows: 300–500 μm CalliSpheres drug-loaded microspheres were loaded with epirubicin, and then slow embolization of tumor supplying artery was performed after microcatheter superselection. Chest enhanced computed tomography and related hematological examination were reviewed after 2 months of DEB-BACE, and the tumor response after the first interventional therapy was evaluated using modified response evaluation criteria in solid tumors. The overall survival (OS) of patients was determined, and the quality of life and the incidence rate of adverse reactions were observed.ResultsFrom January 2019 to January 2021, 43 patients with refractory NSCLC were enrolled. The patients were followed up until June 2022. All 43 patients underwent DEB-BACE 1.79 ± 0.69 times on average. The 3-, 6-, 12-, and 24-month survival rates were 100%, 86.0%, 41.9%, and 11.8%, respectively. The median OS was 11.5 months. After the first interventional treatment, cough and wheezing significantly improved in 31 patients, hemoptysis was effectively controlled in 12 patients, and superior vena cava compression disappeared in 2 patients after 2 times of treatment. The general health status of the patients after treatment significantly improved compared with that before treatment, including the improvement in physical and emotional functions. Fatigue, nausea and vomiting, dyspnea, and insomnia improved significantly after treatment. No serious adverse events, such as spinal cord injury and cerebral embolism, were observed during the perioperative period. The main adverse reaction after DEB-BACE was chest pain (13/43, grade 1) followed by fever (10/43, grade 1–2), which was significantly relieved within 3–5 days after symptomatic treatment. Other adverse reactions included irritating cough, nausea and vomiting, and bone marrow suppression, and the incidence was less than 20%.ConclusionsDEB-BACE was effective and safe in treating refractory NSCLC, which could significantly improve patients’ quality of life and was worthy of clinical promotion and application.

show abstract

“…Systemic chemotherapy also offers only a limited treatment option for patients with advanced bronchogenic carcinoma [6] or pulmonary metastases due to the minimal improvement in survival rate [7] and the relatively high rate of side effects, resulting in an increased demand for new treatment strategies [8,9] and support for the development of locoregional chemotherapy techniques. The main goal of regional techniques is to achieve higher drug concentrations in target tumors while reducing side effects [6].…”

Section: Introductionmentioning

confidence: 99%

“…Das Lungenkarzinom ist im Jahr 2020 trotz der vielfältigen Behandlungsmöglichkeiten mit etwa 11,4 % die am zweithäufigsten diagnostizierte Krebserkrankung und mit 20 % die häufigste Ursache für krebsbedingte Todesfälle [1]. Auch die systemische Chemotherapie bietet für Patienten mit fortgeschrittenem bronchogenen Karzinom [6] oder Lungenmetastasen durch die eher geringe Überlebensverbesserung [7] bei relativ hoher Nebenwirkungsrate nur eine limitierte Therapieoption, was die Nachfrage nach neuen Behandlungsstrategien erhöht hat [8,9] und das Aufkommen der lokoregionalen Chemotherapietechniken begünstigt. Das Hauptziel der regionalen Techniken besteht darin, höhere Wirkstoffkonzentrationen in Zieltumoren bei gleichzeitig reduzierten Nebenwirkungen zu ermöglichen [6].…”

Section: Introductionunclassified

Intravascular Treatment Techniques for Locoregional Therapies of Lung Tumors

Vogl

Mekkawy

Thabet

2023

Rofo

View full text Add to dashboard Cite

Background Lung cancer incidence has greatly increased over the past century. Moreover, the lung is the most common site of metastatic involvement. Despite improvements in the diagnosis and treatment of lung malignancies, patient prognosis is still unsatisfactory. Locoregional chemotherapeutic techniques for the treatment of lung malignancies are the current focus of research. The aim of this review article is to present different locoregional intravascular techniques and their treatment principles and to assess the pros and cons of each of them as a palliative and neoadjuvant treatment method in the treatment of lung malignancy. Method The different methods for the treatment of malignant lung lesions such as isolated lung perfusion (ILP), selective pulmonary artery perfusion (SPAP), transpulmonary chemoembolization (TPCE), bronchial artery infusion (BAI), bronchioarterial chemoembolization (BACE), and intraarteriel chemoperfusion (IACP) are evaluated comparatively. Results Locoregional intravascular chemotherapy procedures are proving to be promising treatment options in the management of malignant lung tumors. In order to achieve optimal results, the locoregional technique should be used to achieve the highest possible uptake of the chemotherapeutic agent into the target tissue with rapid systemic clearance. Conclusion Among the various treatment options for lung malignancies, TPCE is the best evaluated treatment concept. However, further studies are necessary to define the optimal treatment concept with the best clinical outcomes. Key Points Citation Format

show abstract

The Efficacy of Drug-eluting Bead Transarterial Chemoembolization Loaded With Oxaliplatin for the Treatment of Stage III-IV Non-small-cell Lung Cancer

Cited by 6 publications

References 22 publications

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Intravascular Treatment Techniques for Locoregional Therapies of Lung Tumors

Contact Info

Product

Resources

About